NCT03641573View on ClinicalTrials.gov

Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

October 21, 2018

Study Completion Date

October 21, 2018

Conditions
Healthy Volunteer
Interventions
DRUG

[14C] ASN002

\[14C\] ASN002

Trial Locations (1)

53704

Covance Clinical Research Unit, Madison

Sponsors

Lead Sponsor

Asana BioSciences
All Listed Sponsors
lead

Asana BioSciences

INDUSTRY